drug
ABS-0871
Phase 1updated 6mo agoby Actio Biosciences Inc
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
News(4)
- New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programsSetara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.biospace · 18d ago
- Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series ASetara Biosciences, a privately held spinout formed following Jazz Pharmaceuticals' acquisition of Actio Biosciences in September, has raised $90 million in series A financing to advance its clinic…fiercebiotech · 19d ago
- Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelineJazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.biospace · 3mo ago
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.fiercebiotech · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that